Tirzapetide dose escalation schedules were slower in the real-world than clinical settings among individuals with obesity without T2D.

Tirzepatide was associated with better glycemic control and weight loss outcomes than semaglutide and insulin among patients with T2D.

Net loss for the three months ended March 31, 2025, totaled $11.1 million, with non-cash share-based compensation expense of ...

Glucagon-like peptide-1 receptor agonists improve cardiovascular outcomes and reduce mortality in patients with type 2 ...

A novel investigational endoscopic procedure targeting the duodenum appears beneficial in improving glycemic parameters in ...

Ooops... Something went wrong while loading this page.

The results suggested that treatment with tirzepatide was associated with ... providing cutting-edge solutions to advance both clinical research and patient care initiatives.

The filmmaker’s candid post opens a conversation about health, stigma, and promising advances in diabetes and weight ...

GLP-1 receptor agonists remain blockbuster drugs for weight management for people with overweight or obesity. Increasingly, ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...